Editorial
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?
Abstract
In the last 10 years, the prognosis of advanced non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations has dramatically improved, since the introduction of selective EGFR-tyrosine kinase inhibitors (TKIs).
